How Many Patients with Type 2 Diabetes Meet the Inclusion Criteria of the Cardiovascular Outcome Trials with SGLT2 Inhibitors? Estimations from a Population Database in a Mediterranean Area

OBJECTIVE: Regulatory agencies require the assessment of cardiovascular (CV) safety for new type 2 diabetes (T2D) therapies through CV outcome trials (CVOTs). However, patients included in CVOTs assessing sodium-glucose cotransporter-2 inhibitors (SGLT2i) might not be representative of those seen in...

Descripción completa

Detalles Bibliográficos
Autores principales: Canivell, Silvia, Mata-Cases, Manel, Vlacho, Bogdan, Gratacòs, Mònica, Real, Jordi, Mauricio, Dídac, Franch-Nadal, Josep
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6877986/
https://www.ncbi.nlm.nih.gov/pubmed/31815146
http://dx.doi.org/10.1155/2019/2018374

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6877986/
https://www.ncbi.nlm.nih.gov/pubmed/31815146
http://dx.doi.org/10.1155/2019/2018374

Ejemplares similares